Multiple myeloma incidence and mortality trends in the United States, 1999-2020

Author:

Zhu David T.1,Park Andrew1,Lai Alan1,Zhang Lingxiao2,Attar Hiba3,Rebbeck Timothy R.4

Affiliation:

1. Virginia Commonwealth University

2. Yale School of Public Health

3. Schulich School of Medicine & Dentistry

4. Dana-Farber Cancer Institute, Harvard TH Chan School of Public Health

Abstract

Abstract

Multiple myeloma (MM) is a plasma cell disorder accounting for approximately 10% of hematologic malignancies. There is limited epidemiological evidence regarding the long-term trends and disparities in MM in the US. We conducted a multiple time point cross-sectional study using MM incidence rate data from the Surveillance, Epidemiology, and End Results (SEER) database and mortality data from the CDC Wide-Ranging Online Data for Epidemiologic Research (CDC WONDER) Underlying Cause of Death database between 1999 and 2020. During this period, MM incidence has steadily increased, while MM mortality has steadily decreased, with substantial racial and ethnic disparities. Non-Hispanic Black individuals exhibited the highest incidence rates, which consistently rose from 12.02 (95% CI: 10.54, 13.64) in 1999 to 14.20 (95% CI: 12.93, 15.55) per 100,000 population by 2020. Non-Hispanic American Indian/Native Alaskans and Asian/Pacific Islanders demonstrated the lowest incidence rates of 5.59 (95% CI: 2.69, 10.04) and 3.56 (95% CI: 2.94, 4.27) per 100,000 population in 1999 to 5.76 (95% CI: 3.49, 8.90) and 3.92 (95% CI: 3.46, 4.42) per 100,000 population, respectively, by 2020. Disparities by gender, age, tumor stage, US census region, and rurality were observed, underscoring the importance of targeted, equity-centered interventions and MM screening initiatives for at-risk populations.

Publisher

Research Square Platform LLC

Reference51 articles.

1. Albagoush, S. A., Shumway, C., Azevedo, A. M. Multiple myeloma. online https://www.ncbi.nlm.nih.gov/books/NBK534764/ (2023).

2. Impact of CRAB symptoms in survival of patients with symptomatic myeloma in novel agent era;Nakaya A;Hematol Rep,2017

3. Global burden of multiple myeloma: a systematic analysis for the Global Burden of Disease Study 2016;Cowan AJ;JAMA Oncol,2018

4. International myeloma working Group updated criteria for the diagnosis of multiple myeloma;Rajkumar SV;Lancet Oncol,2014

5. Diagnosing myeloma in general practice: how might earlier diagnosis be achieved?;Smith L;Br J Gen Pract,2022

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3